Paclitaxel: all 2,132 studies that test it

Page 2 of 22. Open to participants first (342), then studies with results posted, then the rest; newest registration first within each.

• The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ ECNot yet recruitingNCT06965829Phase 2
• DT2216 + Paclitaxel in Platinum-Resistant Ovarian CancerRecruitingNCT06964009Phase 1
• A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Phase 3
• AK129 Combination Therapy for Advanced Solid TumorsRecruitingNCT06943820Phase 1/2
• Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical CancerRecruitingNCT06942416Phase 2
• SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT06927180Phase 2
• Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ CancerNot yet recruitingNCT06904300Phase 2
• Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 2
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingNCT06897644Phase 3
• A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06894459Phase 2
• Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type AdenocarcinomaNot yet recruitingNCT06870565Phase 3
• A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal CancerRecruitingNCT06869226Phase 2
• Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCCNot yet recruitingNCT06861894Phase 2
• Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.RecruitingNCT06856213Phase 2
• Second-line Immunotherapy for ES-SCLCRecruitingNCT06853678Not applicable
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
• NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer PatientsRecruitingNCT06845319Phase 2
• A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingNCT06843447Phase 1/2
• Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast CancerNot yet recruitingNCT06835400Phase 3
• Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm TrialRecruitingNCT06818331Phase 2
• Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJRecruitingNCT06808971Phase 2
• Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine CancerRecruitingNCT06795009Phase 1
• A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCCNot yet recruitingNCT06793761Phase 2
• Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ CancerRecruitingNCT06791148Phase 2
• Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic CancerRecruitingNCT06789679Phase 2
• Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06764355Phase 2
• A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast CancerNot yet recruitingNCT06746870Phase 2
• Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06728618Phase 2
• Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid CancerNot yet recruitingNCT06713057Phase 2
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingNCT06712316Phase 2/3
• An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung CancerRecruitingNCT06693336Phase 2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesRecruitingNCT06675136Phase 1
• Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentNot yet recruitingNCT06662877Phase 2/3
• IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialRecruitingNCT06654011Phase 2
• Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerRecruitingNCT06637306Early Phase 1
• Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Phase 2
• Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
• BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial CancerNot yet recruitingNCT06620029Phase 1/2
• Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal CarcinomaRecruitingNCT06611150Phase 1
• Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingNCT06601309Phase 2
• Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 2
• LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic PatientsRecruitingNCT06576635Not applicable
• Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic CancerRecruitingNCT06576115Phase 2
• Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCANot yet recruitingNCT06569225Phase 2
• Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial CancerRecruitingNCT06561308Phase 2
• Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyRecruitingNCT06538896Phase 2
• Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLCRecruitingNCT06532591Phase 2
• Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial CarcinomaRecruitingNCT06532539Phase 2
• Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingNCT06519591Phase 2
• Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCCNot yet recruitingNCT06508229Phase 2
• Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruitingNCT06493019Phase 2
• Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersRecruitingNCT06492070Phase 2
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingNCT06483555Phase 1/2
• Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking SurgeryRecruitingNCT06476184Phase 3
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
• Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLCRecruitingNCT06467617Phase 2
• Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerRecruitingNCT06463028Phase 2
• Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT06459687Phase 3
• Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
• Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingNCT06446206Phase 2
• Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingNCT06445972Phase 1/2
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingNCT06441890Phase 2
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian CancerRecruitingNCT06437353Phase 2
• Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.Not yet recruitingNCT06426056Phase 2
• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT06423326Phase 2
• A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06415669Phase 2
• A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC PatientsRecruitingNCT06412471Phase 2
• Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast CancerNot yet recruitingNCT06407310Phase 2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast CancerNot yet recruitingNCT06404736Phase 2
• Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal CancerRecruitingNCT06403878Phase 2
• Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical CancerRecruitingNCT06391190Phase 1/2
• Newly Emerging Immunotherapy for Pancreatic Cancer TreatmentNot yet recruitingNCT06370754Phase 1/2
• PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence PatientsRecruitingNCT06359275Phase 2
• A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.Not yet recruitingNCT06339216Phase 2
• Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT06331845Phase 2
• Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal CancerRecruitingNCT06323460Phase 2
• Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06320405Phase 1/2
• Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06303583Phase 1/2
• Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene MutationsNot yet recruitingNCT06299371Phase 2
• Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical CancerRecruitingNCT06289751Phase 2
• Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACCRecruitingNCT06288373Phase 2/3
• Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical CarcinomaRecruitingNCT06241235Phase 1/2
• Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT06235918Phase 2
• Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingNCT06222944Phase 2
• DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
• Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving SurgeryRecruitingNCT06209294Phase 2
• A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal AdenocarcinomaRecruitingNCT06207305Phase 1/2
• Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1
• Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction CarcinomaNot yet recruitingNCT06198465Phase 2
• Transcatheter Arterial Infusion to Patients With Advanced Pancreatic CancerRecruitingNCT06196788Phase 2
• ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingNCT06182072Phase 1
• Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction AdenocarcinomaRecruitingNCT06163729Phase 2
• Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
• The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.Not yet recruitingNCT06140576Phase 1/2
• Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell CarcinomaRecruitingNCT06122493Phase 2
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT06121570Phase 1
• Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT06109402Phase 2

← Paclitaxel overview